Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Drug Profile

Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; Bone-marrow-derived-mesenchymal-stem-cells-BrainStorm; GDNF therapy; GDNf-stem-cell-therapy-BrainStorm-Cell-Therapeutics; Glial-cell-line-derived neurotrophic factor stem cell therapy - BrainStorm Cell Therapeutics; Glial-cell-line-derived-neurotrophic-factor-stem-cell-therapy-BrainStorm; MSC-NTF; MSC-NTF-BrainStorm-Cell-Therapeutics; Neurotrophic factor-secreting stem cell therapy; Neurotrophic-factor-producing-adult-stem-cell-therapy-BrainStorm; NurOwn; NurOwn-GDNF-therapy; NurOwn™ program one

Latest Information Update: 02 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Antiparkinsonians; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Preclinical Autistic disorder; Multiple sclerosis
  • No development reported Huntington's disease; Parkinson's disease; Sciatica; Spinal cord injuries

Most Recent Events

  • 29 Oct 2018 BrainStorm Cell Therapeutics announces intention to submit an IND application to the US FDA for an Undisclosed indication
  • 13 Sep 2018 BrainStorm Cell Therapeutics has patent protection for NurOwn® generation in USA
  • 12 Sep 2018 BrainStorm announces intention to submit BLA to US FDA for Amyotrophic lateral sclerosis in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top